Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase III trial of pulsed Inhaled Nitric Oxide (iNO) in treatment of patients with pulmonary arterial hypertension (PAH)

Trial Profile

Second phase III trial of pulsed Inhaled Nitric Oxide (iNO) in treatment of patients with pulmonary arterial hypertension (PAH)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms INOvation-2
  • Most Recent Events

    • 13 Mar 2017 Status changed from planning to withdrawn prior to enrolment, according to a Bellerophon Therapeutics media release. This study has been replaced with a randomized withdrawal study (profile 280452) that will recruit approximately 40 patients from INOvation-1 study.
    • 04 Jan 2017 According to a Bellerophon Therapeutics media release, company has received confirmation from the USFDA for acceptance of modifications to its Phase 3 program for INOpulse in Pulmonary Arterial Hypertension (PAH). Under the newly modified Phase 3 program, INOvation-1 and other confirmatory trial (see profile 280452, replacing the INOvation-2 study) will support a New Drug Application filing for INOpulse in PAH subjects on long term oxygen treatment (LTOT).
    • 04 Jan 2017 Planned number of patients changed from 270 to 282, as reported in a Bellerophon Therapeutics media release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top